Summit Therapeutics Inc.

Summit ended 2025 with approximately $713.4 million in cash and no debt. Total GAAP operating expenses for Q4 2025 were $225 million, down from $234.2 million in Q3 2025, while non-GAAP operating expenses were $113.3 million versus $103.4 million in Q3. The Q4 GAAP decline was mainly due to lower stock-based compensation of $19.1 million, partly offset by $8.8 million higher clinical trial spend; the non-GAAP increase was mainly from higher R&D tied to HARMONi-3 and HARMONi-7. For the full year 2025, G&A spend excluding stock-based compensation was approximately $43 million, with a quarterly run rate of about $10 million to $11 million. Forward-looking, Summit expects the HARMONi-3 squamous cohort interim PFS analysis in Q2 2026, final PFS and interim OS in the second half of 2026, non-squamous enrollment to finish in the second half of 2026 with final PFS in the first half of 2027, and it continues to target a potential U.S. decision on HARMONi for November 14, 2026.

Maky Zanganeh emphasized that Summit is moving quickly to broaden ivonescimab’s clinical reach while preparing for commercialization. She highlighted the HARMONi-3 protocol change as a way to get data to regulators sooner, the new GORTEC-led head and neck study, and additional collaborations with Revolution Medicines and GSK. Her tone was confident and mission-driven, repeatedly framing ivonescimab as a differentiated asset with broad potential across solid tumors.

Manmeet Soni focused on cash, spend discipline, and operational readiness. He said Summit had approximately $713.4 million in cash and no debt at year-end 2025, and he pointed out that non-GAAP operating expenses rose to $113.3 million in Q4 from $103.4 million in Q3, largely due to R&D for HARMONi-3 and HARMONi-7. He also noted that G&A excluding stock comp was about $43 million for 2025, with a quarterly run rate of roughly $10 million to $11 million, and said manufacturing transfer and validation to a U.S.-based manufacturer was completed.

Analysts focused heavily on why Summit added an interim PFS readout for HARMONi-3 and whether that changes the regulatory path if OS is still immature. Management said the move is intended to accelerate discussions with FDA using data in hand, while preserving the trial’s integrity and keeping the final PFS and OS timing unchanged. Questions also centered on whether front-line lung cancer approvals could eventually be supported by PFS plus OS trends, and management said the magnitude of benefit and OS maturity both matter. On the new head and neck program, management said GORTEC approached Summit, the 3-arm design should help show contribution of components, and a U.S. expansion would depend on enrollment and additional data, but no specifics were given.